• ADC Therapeutics launched a financial restructuring built around an $86.6 million PIPE, expected to close Oct. 22, 2026.
• Royalty financing was amended to remove a $150 million change-of-control payment, easing takeover-related liabilities.
• Senior secured term loan was refinanced via a $70 million prepayment, cutting outstanding principal to $50 million with an August 2029 bullet maturity.
• Revised loan terms removed the minimum liquidity covenant, setting a trailing four-quarter U.S. ZYNLONTA sales covenant at $65 million from Q4 2026.
• Pro forma cash and cash equivalents were about $196 million as of Sept. 30, 2026, reflecting PIPE proceeds and the loan prepayment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief via PR Newswire (Ref. ID: NY66764) on October 08, 2026, and is solely responsible for the information contained therein.